Fluoxetine half life

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Fluoxetine Half-Life: Key Insights from Research

Introduction to Fluoxetine Pharmacokinetics

Fluoxetine, a widely used selective serotonin reuptake inhibitor (SSRI), is known for its unique pharmacokinetic properties. Understanding its half-life is crucial for optimizing its therapeutic use and managing potential side effects.

Fluoxetine and Norfluoxetine Half-Life

Fluoxetine Half-Life

Fluoxetine is well absorbed after oral administration and has a half-life ranging from 1 to 4 days Altamura1994Lemberger1985Sommi1987. This variability is due to its nonlinear pharmacokinetic profile, meaning that its metabolism and elimination do not follow a straightforward pattern Altamura1994Sommi1987.

Norfluoxetine Half-Life

Norfluoxetine, the active metabolite of fluoxetine, has a significantly longer half-life, ranging from 7 to 15 days Altamura1994Lemberger1985Sommi1987. This extended half-life contributes to the prolonged therapeutic effects and the potential for sustained side effects even after discontinuation of the drug.

Implications of Long Half-Life

Therapeutic Window and Dosing Strategies

The long half-life of fluoxetine and norfluoxetine allows for flexible dosing strategies. For instance, studies have shown that fluoxetine can be effectively administered once every third day or even once weekly after an initial period of daily dosing D2003Wagstaff2001Burke2000+1 MORE. This can improve patient compliance and reduce the risk of side effects.

Drug Interactions and Safety

The extended half-life also means that fluoxetine and its metabolite can interact with other medications for a prolonged period. For example, fluoxetine has been shown to impair the clearance of alprazolam but not clonazepam, highlighting the importance of considering drug interactions in clinical practice .

Conclusion

Fluoxetine's half-life of 1 to 4 days and norfluoxetine's half-life of 7 to 15 days play a significant role in its pharmacokinetic profile. These properties allow for flexible dosing regimens and necessitate careful consideration of drug interactions. Understanding these aspects is essential for optimizing fluoxetine's therapeutic use and managing its side effects effectively.

Sources and full results

Most relevant research papers on this topic

Clinical Pharmacokinetics of Fluoxetine

Fluoxetine is well absorbed and has a nonlinear pharmacokinetic profile, making it suitable for elderly patients with depression, but should be used with caution in patients with reduced metabolic capability.

Highly Cited

1994·

326citations

·A. Altamura et al.

Clinical Pharmacokinetics·

DOI

Fluoxetine: clinical pharmacology and physiologic disposition.

Fluoxetine is well absorbed after oral administration, shows dose proportionality, and has similar pharmacokinetics in elderly and healthy subjects.

Non-RCTHighly Cited

1985·

210citations

·L. Lemberger et al.

The Journal of clinical psychiatry

Fluoxetine once every third day in the treatment of major depressive disorder

Fluoxetine can effectively treat major depressive disorder, but a higher daily dose has a reduced relapse rate compared to lower daily doses.

RCT

2003·

0citations

·D. D et al.

European Archives of Psychiatry and Clinical Neuroscience·

DOI

Once-Weekly Fluoxetine

Once-weekly fluoxetine 90mg for depression treatment maintains patient compliance and is well-tolerated, with a tolerability profile similar to that of the immediate-release formulation.

RCT

2001·

12citations

·Antona J. Wagstaff et al.

Drugs·

DOI

Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.

Weekly dosing of fluoxetine is well-tolerated and potentially as effective as daily dosing in maintaining therapeutic response in subjects with major depressive disorder.

RCT

2000·

25citations

·William J. Burke et al.

Journal of clinical psychopharmacology·

DOI

Fluoxetine: A Serotonin‐specific, Second‐generation Antidepressant

Fluoxetine is a serotonin-specific, second-generation antidepressant with comparable efficacy to tricyclic agents and low side effects.

Highly Cited

1987·

138citations

·R. Sommi et al.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy·

DOI

Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder.

Once-weekly dosing of fluoxetine, ranging from 10 to 60 mg, is an effective and cost-saving maintenance treatment for patients with panic disorder initially treated with daily fluoxetine.

1999·

14citations

·Emmanuel Np et al.

The Journal of clinical psychiatry·

DOI

Brain Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and Fluoxetine by Fluorine Magnetic Resonance Spectroscopy

Fluvoxamine has a shorter brain elimination half-life than fluoxetine-norfluoxetine, which may help understand treatment modifications and side effects.

Non-RCTHighly Cited

2000·

199citations

·N. Bolo et al.

Neuropsychopharmacology·

DOI

Fluoxetine hydrochloride (Prozac) toxicity in a neonate.

Fluoxetine toxicity in a newborn may be caused by the parent compound, fluoxetine, and side effects may be caused by the parent compound.

Case ReportHighly Cited

1993·

129citations

·M. Spencer

Pediatrics·

DOI

Fluoxetine impairs clearance of alprazolam but not of clonazepam

Fluoxetine impairs clearance of alprazolam through microsomal oxidation but does not alter clonazepam clearance through nitroreduction.

RCTHighly Cited

1992·

138citations

·D. Greenblatt et al.

Clinical Pharmacology & Therapeutics·

DOI

Try another search

therapy for social anxiety

hyperactivity in teenager

emotional stress symptoms

mounjaro drug

types of anxiety meds

physical symptoms of stress and anxiety